Bioventus (BVS) Net Income towards Common Stockholders Growth (3y) (2023 - 2026)
Powered by 
Analysis
Bioventus (BVS) Net Income towards Common Stockholders Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -12.28% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 24.56% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 22.97% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 20.02% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 51.47% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -7.83% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 29.05% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 17.54% |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn | 112.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 27, 2026 | 112.92% |
| Mar 28, 2026 | 26.47% |
| Dec 31, 2025 | 33.62% |
| Sep 27, 2025 | 26.57% |
| Jun 28, 2025 | 46.70% |
| Mar 29, 2025 | 39.23% |
| Dec 31, 2024 | -188.93% |
| Sep 28, 2024 | -37.11% |
| Jun 29, 2024 | -46.96% |
| Mar 30, 2024 | -31.23% |
| Dec 31, 2023 | -75.45% |
| Sep 30, 2023 | -45.87% |
| Jul 1, 2023 | 7.51% |
| Apr 1, 2023 | -165.13% |